Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, patients with severe alopecia areata treated with baricitinib over 152 weeks experienced sustained patient-reported improvements in scalp, eyebrow, and eyelash hair regrowth, with higher responders observed in the 4mg dose group compared to the 2mg group.

This study found that ritlecitinib 50 mg offered a lower cost per responder than baricitinib 2 or 4 mg for treating severe alopecia areata at Weeks 24 and 52, potentially influencing reimbursement decisions.

In this study, researchers demonstrated that the Id2 gene acts as a direct target and effector of BMP signaling, playing a key role in maintaining quiescence in hair follicle stem cells in vivo.

In this phase 3 trial, baricitinib showed effectiveness and safety in both adolescents and adults with severe alopecia areata, with adolescents achieving higher response rates despite more severe baseline conditions, suggesting the advantages of early treatment.

Baricitinib helps with early hair regrowth in people with alopecia areata.

In this study, baricitinib was evaluated for its effectiveness in promoting concurrent regrowth of scalp hair, eyebrows, and eyelashes in patients with severe alopecia areata, showing clinically meaningful responses compared to placebo.

In this study, PGD2 was shown to increase testosterone production in human keratinocytes through reactive oxygen species, suggesting potential benefits of antioxidants like N-acetyl-cysteine for AGA patients.

This study observed that Icariside II, an extract from Epimedium brevicornu Maxim, can inhibit the growth of gastric cancer in cell lines and mouse models by promoting apoptosis and suppressing the Wnt/β-catenin signaling pathway, with minimal toxicity to normal gastric cells.

This study found that at Week 52, baricitinib resulted in significant hair regrowth for many patients with severe alopecia areata, with 41.6% on the higher dose achieving substantial improvement in scalp hair loss, though some may need longer treatment for optimal benefit.

The trial is ongoing, but researchers are evaluating the efficacy and safety of REZPEG, a potential new therapy for severe alopecia areata, which selectively expands regulatory T cells.

In this phase II clinical study, combining anlotinib with standard platinum-based chemotherapy showed promising outcomes and prognosis in treating extensive small-cell lung cancer, with high disease control and response rates.

In this study, 40.9% of patients taking 4 mg baricitinib and 21.2% taking 2 mg achieved significant hair regrowth over 52 weeks, indicating potential long-term benefits for adults with severe alopecia areata without introducing new safety concerns.

In this study, a strong positive correlation was found between clinician-reported and patient-reported measures for assessing eyebrow and eyelash hair loss in patients with severe alopecia areata, indicating high agreement during treatment with baricitinib over 52 weeks.

This study identifies Activin A and follistatin as key regulators of hair cell differentiation in the mouse auditory sensory epithelium, influencing the timing and pattern of hair cell development.

This study observed that Aconiti Ciliare Tuber extract may promote hair growth in mice by activating the Wnt/β-catenin signaling pathway.

CTP-543 significantly improved eyebrow and eyelash regrowth and patient satisfaction in adults with alopecia areata.

This study found that carbonic anhydrase II was significantly upregulated in human keratinocytes when treated with toll-like receptor 3 agonist and Th2 cytokines, suggesting its potential role in inflammatory skin conditions.

This study found that applying BMP2 stimulated limited regeneration of the amputated P2 bone in mice, but only when applied during a specific "regeneration window" after injury.

This Phase II study found that BAY 43-9006, given at 400 mg orally twice daily, led to stable disease in 30% and tumor reduction in 40% of renal cell carcinoma patients.

This study found that VDAC2 promotes apoptosis in secondary hair follicle stem cells of Albas cashmere goats by activating the P53 signaling pathway, with knockdown of VDAC2 reducing apoptosis and a P53 inhibitor partially rescuing VDAC2-induced apoptosis.

This study focused on baricitinib's effect on patients with severe alopecia areata, highlighting its efficacy for hair regrowth and its potential to improve health-related quality of life and psychological symptoms, as seen in two phase 3 trials.

In this study, treatment with IL-2C to expand Tregs effectively halted hair loss progression in a murine model of alopecia areata.

This study found that MAP-2 is intensely expressed in the companion layer of the hair follicle, suggesting its potential importance to follicle integrity and possible involvement in some types of alopecia.

This study reports that baricitinib was more effective than placebo in promoting hair growth in adults with severe alopecia areata after 36 weeks of treatment in clinical trials.

In a murine model of alopecia areata, this study observed that the IL-2 fusion protein HCW9302 helped prevent disease development by expanding regulatory T cells and reducing disease-causing effector T cell infiltrates, suggesting potential for using IL-2 fusion proteins in alopecia areata treatment.

This study explored the role of Twist2 in fetal wound healing in embryonic mice, observing that its expression was vital for scarless regeneration and normal hair follicle formation; Twist2 knockdown led to visible scars and defective follicle formation.

This study found that more than half of patients with severe alopecia areata who reduced their baricitinib dose from 4mg to 2mg maintained a clinical response for up to 2 years.

This study found that the transcription factor GLABRA 2 inhibits ethylene production, regulating root hair growth in Arabidopsis under nutrient deficiency conditions.

In these randomized, placebo-controlled trials, patients with alopecia areata who received baricitinib showed significantly higher eyebrow and eyelash hair regrowth rates compared to placebo, with greater responses observed at the 4 mg dose and in those achieving overall scalp hair improvement by Week 52.

This study found that CD2 could be a potential new therapeutic target for treating patchy-type alopecia areata, suggesting the need for further research into its role.